Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S ADR
WKN: 866931 / Symbol: NVO / Name: Novo Nordisk / Aktie / Pharmazeutika / Large Cap /
122,00 €
-0,41 %
Buy Novo Nordisk A/S ADR
Sell Novo Nordisk A/S ADR
Buy Novo Nordisk A/S ADR
Novo Nordisk A/S (NYSE: NVO) had its price target raised by analysts at BTIG Research from $20.00 to $31.00. They now have a "buy" rating on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at Argus. They set a "buy" rating and a $110.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $120.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its price target raised by analysts at TD Cowen from $105.00 to $115.00. They now have an "outperform" rating on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $120.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its price target raised by analysts at Cantor Fitzgerald from $120.00 to $140.00. They now have an "overweight" rating on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $163.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $156.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its price target raised by analysts at Argus from $125.00 to $160.00. They now have a "buy" rating on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $163.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Metlife Inc. diskutieren